A glycoengineered therapeutic anti-HBV antibody that allows increased HBsAg immunoclearance improves HBV suppression in vivo

A glycoengineered therapeutic anti-HBV antibody that allows increased HBsAg immunoclearance improves HBV suppression in vivo

Introduction: The effective and persistent suppression of hepatitis B surface antigen (HBsAg) in patients with chronic HBV infection (CHB) is considered to be a promising approach to achieve a functional cure of hepatitis B. In our previous study, we found that the antibody E6F6 can clear HBsAg thro...

Full description

Bibliographic Details
Main Authors: Min You, Fentian Chen, Chao Yu, Yuanzhi Chen, Yue Wang, Xue Liu, Xueran Guo, Bing Zhou, Xin Wang, Boya Zhang, Mujin Fang, Tianying Zhang, Ping Yue, Yingbin Wang, Quan Yuan, Wenxin Luo
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Pharmacology
Subjects:
HBsAg
chronic hepatitis B infection
therapeutic antibody
phagocytosis
neutralization
defucosylation
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1213726/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1213726/full

Similar Items